RE:RE:RE:Sunlenca “CAPELLA was conducted in 72 heavily treatment-experienced patients with multiclass resistant HIV-1. Patients were required to have a viral load ≥ 400 copies/mL, documented resistance to at least two antiretroviral medicinal products from each of at least 3 of the 4 classes of antiretroviral medicinal products (NRTI, NNRTI, PI and INSTI), and no more than 2 fully active antiretroviral medicinal products from the 4 classes of antiretroviral medicinal products remaining at baseline due to resistance, intolerability, medicinal product access, contraindication, or other safety concerns.”
https://www.nejm.org/doi/full/10.1056/NEJMoa2115542
I wondered if third line or forth line(resistant to at least three or 4 failed ART cocktails)groups of patients which Trogarzo is targeting apparently “2000” or so
patients only why Gilded even bother to develop a drug for such a small market?
Well it seems like they are approved based on their clinical trial for the “at least”second line. They will be targeting bigger market, however the drug was not approved (based on their trial’s design)for at least three confirmed resistance as Trogarzo was. Point is it seems like the are not targeting the same market due to the fact the drug might not be effective for that market. One has to dig deep as the headlines is new drug for MDR patients but not highlighting which group!